Advertisements

Neurozepam

Quick links to important sections

Neurozepam

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Neurozepam

Property Description
Active ingredient Bromazepam (INN)
Form Tablets (Oral dosage form)
Pharmacological class CNS depressant / 1,4-Benzodiazepine
General purpose Anxiolytic agent / Tranquilizer
Origin Synthetic compound

Classification and Chemical Identity

Neurozepam is a synthetic psychotropic medication whose primary function is to act as an anxiolytic agent, helping to calm activity in the central nervous system (CNS). Its core active ingredient is Bromazepam, which is classified within the 1,4-Benzodiazepine family of drugs. Bromazepam is categorized as a CNS depressant. This classification is essential, as it indicates the medication is designed to reduce overall neuronal excitability. It is available only as a prescription-only medicine.

The General Purpose of a CNS Depressant

The medication's primary general purpose is to serve as a tranquilizer that provides relief from symptoms associated with high inner tension and restlessness. Bromazepam is recognized for its capacity to reduce emotional distress and general anxiety. This means the medication helps manage both the psychological experience of severe worry and the physical manifestations of tension, such as muscle tightness, a common presentation in pathological anxiety. The overall benefit is the establishment of a calmer state, a physiological action characteristic of a short-to-intermediate acting compound, providing focused relief.

Composition and Dosage Form

Neurozepam is an oral dosage form presented as tablets, and it functions as a single-entity product. Its high-level composition consists solely of the Bromazepam active ingredient combined with solid pharmaceutical excipients necessary for formulation. The standardized tablet form, being a synthetic compound, ensures a consistent and precise delivery of the active ingredient for reliable therapeutic effects. Bromazepam is a well-established substance in this therapeutic space, with other popular brands containing the same formulation including Lexotan and Lexomil used across different international markets.

Advertisements

What side effects are possible with Neurozepam?

Possible side effects and safety information

The safety profile of Neurozepam (Bromazepam) is defined by effects consistent with its regulatory classification as a CNS depressant. Officially documented adverse reactions are grouped by the affected physiological system, following established regulatory classifications.

General CNS and Psychiatric Effects

The most commonly expected effects, consistent with its mechanism, include drowsiness, sedation, decreased alertness, dizziness, ataxia (impaired coordination), and fatigue. These effects, along with headache, may be more pronounced at the initiation of therapy. Psychiatric reactions reported in the label include a confusional state and emotional disorder. The label also documents the potential for anterograde amnesia, where the risk increases with higher dosages and may occur several hours after administration.

System-Organ Classifications and Serious Risks

Adverse reactions are classified across several organ systems, including the nervous system, gastrointestinal (e.g., nausea, dry mouth), and musculoskeletal (e.g., muscle weakness) systems. A key safety consideration is the potential for respiratory depression, a serious risk documented in regulatory documents, especially when the medicine is used concomitantly with other CNS depressants, which may lead to severe sedation, coma, or death.

Dependence, Withdrawal, and Specific Populations

Use of this medication carries the risk of developing physical and psychological dependence, with the risk increasing with the duration and dose of treatment. Abrupt cessation of use is associated with withdrawal symptoms and rebound phenomena, which can include anxiety, tension, and in severe cases, convulsions. Older adults are at a heightened risk for over-sedation, ataxia, and falls. The medicine is contraindicated in patients with conditions like severe hepatic insufficiency due to the risk of precipitating hepatic encephalopathy, and in those with severe respiratory insufficiency.

Advertisements

Overdose and Emergency Response

Neurozepam Overdose and When to Seek Help

Overdose of Neurozepam (Bromazepam) is characterized by manifestations of Central Nervous System (CNS) depression. Severity is dose-dependent and typically presents as enhanced pharmacological effects, including somnolence, lethargy, confusion, ataxia, and slurred speech. In some cases, overdose may lead to hypotonia and areflexia.


Regulatory-Mandated Actions and Severe Outcomes

  • Life-Threatening Risks: Severe toxicity can progress to respiratory depression, apnea, and coma. The risk of these life-threatening outcomes is significantly increased when Neurozepam is taken with other CNS depressants, such as alcohol or opioids.

  • When to Seek Help: Regulatory guidance mandates that patients seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if severe manifestations, such as breathing difficulty or loss of consciousness, are evident.

  • Management and Antidote: Management is based on symptomatic and supportive treatment, requiring close observation and continuous monitoring of vital signs. Flumazenil is the specific benzodiazepine antagonist, but its use is restricted and contraindicated under specific regulatory-defined conditions due to the risk of precipitating adverse effects. Pediatric and elderly patients are noted as specific populations requiring careful attention.

Advertisements

Therapeutic Uses of Neurozepam

What Neurozepam Treats: Main Uses and Benefits

Neurozepam (Bromazepam) is primarily an anxiolytic agent used to provide support in situations involving certain distressing symptoms and periods of significant tension. Its use focuses on symptoms that are severe, disabling, or subjecting the individual to extreme distress.

The medication is commonly applied in conditions characterized by periods of heightened symptoms such as Generalized Anxiety Disorder (GAD), anxiety neuroses, and acute panic states. It may assist with easing emotional distress and helps address symptom clusters that are symptoms related to systemic imbalance, including functional physical symptoms like muscle tension, stress-induced rapid heart rate, and anxiety-related gastrointestinal issues.

It is commonly used when short-term symptomatic assistance is needed during phases when symptoms become momentarily overwhelming or interfere with daily functioning. Through its role in managing psychological tension and somatic discomfort, the medication contributes to general well-being during symptomatic phases and supports patients during difficult episodes by easing distress.

“...relevant when supportive symptom management is appropriate for stabilization.”

Symptomatic Support for Severe Tension
Neurozepam is considered relevant for managing excessive psychological tension and associated physical strain, relevant in conditions where symptoms may intensify temporarily

Regulatory References

  1. Health Canada's product monograph
Advertisements

Eligibility and Restrictions for Use

Neurozepam (Bromazepam) is an oral dosage form approved for use only in adults for the short-term symptomatic management of severe anxiety and tension. The drug's eligibility profile, as defined by global regulatory bodies, is governed by several absolute contraindications and population-specific restrictions.

Populations Who Must Not Use (Contraindications)

Official labeling prohibits use in patients with the following conditions:

  • Severe Respiratory Insufficiency or Sleep Apnea Syndrome.
  • Severe Hepatic Insufficiency.
  • Myasthenia Gravis.
  • Known Hypersensitivity to any Benzodiazepine derivative.

Restricted and Ineligible Populations

The medication is not recommended for Pediatric Patients (under 18 years), as safety and efficacy in this age group have not been formally established by regulators. For Older Adults ( geq 65 years), use is permitted but is conditional, requiring explicit caution and often a reduced starting dose. Neurozepam is not recommended during Pregnancy and is contraindicated for Lactating Women, as the active substance passes into breast milk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Neurozepam

Interaction scope

The documented interaction profile for Neurozepam is structured around two primary categories of substances: other Central Nervous System (CNS) depressants and medicines that inhibit its metabolic clearance.

  • Medicinal Product Categories: Opioids (Analgesics), Other CNS Depressants (e.g., Sedative Hypnotics, Antipsychotics), and Potent CYP 3A4 Inhibitors.
  • Specific Interacting Agents: Examples of strong CYP 3A4 inhibitors, such as certain azole antifungals and protease inhibitors, are cited in regulatory sources for the benzodiazepine class due to their effect on drug clearance.
  • Mechanistic Basis: The interactions are classified as Pharmacodynamic (additive CNS depression) and Pharmacokinetic (inhibition of oxidative metabolism/reduced clearance).

Interaction-related Restrictions

Co-administration with Opioids is subject to stringent regulatory constraints, requiring use to be reserved only for patients for whom alternative treatment options are deemed inadequate. The official regulatory warnings emphasize that concomitant use with alcohol (ethanol) and/or other CNS depressants must be avoided due to the potential for a severe increase in the clinical effects of Neurozepam.

Official Interaction Statements:

  • Co-administration with Opioids is documented as a pharmacodynamic interaction that may result in profound sedation, respiratory depression, coma, and death.
  • Co-administration with other CNS depressants or alcohol produces additive CNS depressant effects, which increases the risk of severe sedation.
  • The pharmacokinetic interaction with potent CYP 3A4 inhibitors reduces the clearance of Bromazepam, leading to an increase in systemic plasma concentration/exposure and increased risk of adverse reactions.

Connection to the overall interaction profile

The regulatory interaction profile for Neurozepam is primarily defined by a high pharmacodynamic risk of additive CNS depression when combined with other central nervous system depressants. This critical effect requires stringent regulatory constraints on co-administration, as mandated in the official product monographs. Additionally, the profile includes a pharmacokinetic risk of increased exposure due to the susceptibility of its metabolic clearance pathway to strong CYP 3A4 inhibitors.

Advertisements

Mechanism of Action

Neurozepam functions as a positive allosteric modulator of the GABA A receptor complex, specifically targeting GABA A receptors composed of alpha 1, alpha 2, alpha 3, and alpha 5 subunits, often in combination with beta 2/beta 3 and gamma 2 subunits, which are concentrated postsynaptically in the central nervous system.

The Neurozepam molecule binds to an allosteric site located at the interface between the alpha and gamma 2 subunits. This binding event does not directly open the receptor's integral chloride ion channel. Instead, it induces a conformational change in the receptor protein, increasing the receptor's affinity for the endogenous neurotransmitter GABA and enhancing the efficiency of the channel opening.

This molecular interaction results in a leftward shift of the GABA dose-response curve, meaning that for any given concentration of GABA, the frequency of chloride channel opening is significantly increased. The intracellular consequence is a heightened influx of negatively charged chloride ions ( Cl^-) into the postsynaptic neuron.

The resulting hyperpolarization of the neuronal cell membrane, designated as a postsynaptic inhibitory potential, elevates the threshold required for action potential generation. This systemic consequence is a generalized reduction in neuronal excitability across the central nervous system.

Advertisements

Dosage and Administration Information

Neurozepam, which contains the active substance bromazepam, is a benzodiazepine indicated for the short-term management of anxiety that is severe, disabling, or subjecting the individual to unacceptable distress.

Administration and Dosage

  • Follow Prescriber Instructions: Always take Neurozepam exactly as prescribed by a healthcare professional. Doses are individualized based on the severity of the anxiety, the patient's response, and any specific population considerations, such as age or concurrent illness.
  • Duration of Treatment: The total duration of treatment should be as short as possible, generally no longer than 8–12 weeks, including the dose tapering period. Prolonged use increases the risk of developing tolerance, dependence, and withdrawal symptoms.
  • Method: Swallow the tablet whole with a glass of water. It may be taken with or without food, unless otherwise advised.

Important Considerations

  • Discontinuation: Never stop taking this medication abruptly. Due to the risk of withdrawal reactions, discontinuation must involve a gradual dosage reduction on a schedule determined by your doctor.
  • Missed Dose: If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed one and continue with the regular dosing schedule. Do not double the dose to make up for a missed one.
  • Alcohol and CNS Depressants: Avoid consuming alcohol and other central nervous system (CNS) depressants while taking Neurozepam, as this can significantly increase the risk of severe sedation and respiratory depression.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neurozepam (Bromazepam)

Evidence for Use in Generalized Anxiety and Acute Tension States

Research has explored the use of Neurozepam (Bromazepam) in conditions characterized by fluctuating or episodic manifestations of anxiety and tension. The main evidence comes from short-term randomized controlled trials (RCTs), which is the standard design used in research exploring short-term symptom changes. These studies typically compared the outcomes of patients receiving Neurozepam with those receiving an inactive treatment (placebo).

These acute trials examined changes in outcomes related to episodic or acute changes in anxiety severity, using standardized rating tools. Findings describe patterns observed in the studies related to changes in overall anxiety scores over the treatment period. The follow-up duration for the most common placebo-controlled trials was typically limited to 4 to 6 weeks.

Evidence Addressing Physical Symptoms of Anxiety

Research explored outcomes related to physical discomfort associated with anxiety. This was done primarily through subgroup analyses within the larger anxiety studies. Researchers examined outcomes related to physical discomfort, which included symptoms like muscle tightness or stress-related rapid heart rate, often measured by tracking somatic anxiety factor scores on rating scales.

Studies reported patterns of measured changes in the physical symptom components of the anxiety scores monitored. The evidence is structured as sub-analyses and factor-score assessments within the primary efficacy trials.

Long-Term Studies and Follow-up

For most medications intended for short-term use, long-term data are not fully established through randomized controlled trials. To gain insight into patterns of use over extended periods, research examined data from large observational settings, often monitoring use over periods ranging from one year to several years.

While these studies help show what has been observed so far about the duration of treatment, they cannot establish cause and effect regarding the maintenance of symptom outcomes, as they lack a true control group. The research provides context but not individual predictions about long-term outcomes.

Key Studies & References

  1. Bromazepam, a new anxiolytic: a comparative study with diazepam in general practice
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Neurozepam (FAQ)


Q: Are there any specific foods or drinks that should be avoided when taking Neurozepam?

Regulatory documents advise that intake of grapefruit and grapefruit juice should be avoided while using Neurozepam. This precaution is related to how the body processes the medication, as grapefruit can potentially affect the concentration of the active substance in the bloodstream.


Q: Can Neurozepam be taken with common over-the-counter pain relievers?

Official warnings require caution when co-administering Neurozepam with any other medicine that causes sedation or drowsiness. This includes some over-the-counter products that are known to cause CNS depression, as combining them with Neurozepam may increase the risk of severe sedation.


Q: How long does the effect of Neurozepam typically last in the body?

The duration of the medication's effect is often described by its half-life, which is the time it takes for half of the active substance to be eliminated from the body. For Neurozepam's active ingredient, the average half-life is typically reported as 12 hours, with a range that can vary between individuals.


Q: Can taking Neurozepam affect a person's memory or concentration?

Yes, official product information reports that Neurozepam can affect cognitive functions. Documented effects include decreased alertness, a confusional state, and a potential for anterograde amnesia, which is memory loss for events that occur after the dose is taken. Regulatory warnings indicate that the potential for amnesia may be associated with higher dosages.


Q: What is 'rebound insomnia' or 'rebound anxiety' in relation to Neurozepam?

The term rebound phenomena is used in official warnings to describe the return of symptoms, such as anxiety or insomnia, that may occur when the medicine is stopped. These symptoms can be intensified, or 'rebound,' compared to the severity experienced before treatment began. For this reason, official guidelines indicate that discontinuation requires a gradual dosage reduction.


Q: What should be done with unused or expired Neurozepam?

Due to its controlled substance classification, Neurozepam should be disposed of in a way that prevents misuse. Regulatory guidelines prioritize utilizing an authorized drug take-back program. Historically, instructions have included mixing the medicine with an undesirable substance, sealing it, and discarding it in household trash, as alternatives to flushing it down the toilet.


Q: How is Neurozepam different from other anxiety or sleep medicines?

Neurozepam's active substance is classified as a 1,4-Benzodiazepine by medical authorities. This means it belongs to a specific chemical family and works by affecting a main inhibitory pathway in the brain called the GABA A receptor complex. Other anxiety or sleep medicines may belong to entirely different chemical classes, leading to variations in their intended use or effect profiles.


Q: Is Neurozepam considered a fast-acting medication?

Pharmacokinetic data provides information on how quickly the medicine reaches its peak concentration. According to official information, maximum levels of the drug in the bloodstream, known as peak plasma concentrations, are generally reached between 1 and 4 hours after taking the tablet.


Q: Can Neurozepam be used for short-term or temporary relief?

Regulatory documents indicate that Neurozepam is intended for the short-term management of severe anxiety. The indication is for short-term use, and initial treatment courses are intended for symptomatic relief.


Q: Are there generic versions of Neurozepam available or in development?

The active substance in Neurozepam is bromazepam, which is the non-proprietary name for the compound. Bromazepam is a widely available substance and is marketed internationally under several official brand names, such as Lexotan and Lexomil, depending on the country and manufacturer.


Q: Does Neurozepam treat the underlying cause or just the symptoms?

Neurozepam is officially indicated for the symptomatic relief of severe anxiety and tension. Its mechanism of action is to reduce general neuronal excitability, acting as a tranquilizer. This means the medicine helps manage the observable and emotional symptoms, but it is not described in regulatory documents as a treatment for the underlying cause of the condition.


Q: Does Neurozepam have any known long-term side effects?

While long-term controlled data is limited, regulatory documents emphasize the primary long-term risks associated with its use: the development of physical and psychological dependence and the occurrence of tolerance. These risks are noted to increase significantly with extended duration and higher dosages.


Q: Can Neurozepam cause unexpected reactions like agitation or excitability?

In some cases, the official labeling for this class of medication documents the possibility of paradoxical reactions. These are effects opposite to the expected sedative action and can include behavioral changes such as increased agitation or irritability. These reactions have been observed in specific patient groups, including children and older adults.


Q: What are the signs of a severe allergic reaction to Neurozepam?

Information in patient safety materials documents that signs of a severe allergic reaction could include hives, a rash, or swelling of the face, tongue, or throat. Other serious signs include difficulty breathing or swallowing and severe dizziness. Official documentation describes these signs as requiring immediate attention.


Q: How do the effects of Neurozepam compare to Z-drugs (like zolpidem) for sleep?

Neurozepam is classified as a benzodiazepine, whereas Z-drugs (like zolpidem) are classified as non-benzodiazepine hypnotics. Both classes act on the GABA A receptor complex. Official medical literature notes that differences in their action on the receptor may lead to differences in their clinical profiles, such as the balance of effects related to anxiety relief versus sleep.


Q: Is it common to have a 'hangover' feeling the morning after taking Neurozepam?

Residual effects the morning after administration are reported as possible side effects. These next-day effects can include feelings of dizziness, unsteadiness, or lingering sleepiness. These sensations are consistent with the presence of the drug in the body as it is slowly cleared from the system.


Q: Does Neurozepam affect sleep structure (e.g., REM sleep)?

Medical literature concerning the drug class indicates that benzodiazepines, like Neurozepam, can affect sleep architecture. The class of drug is typically associated with prolonging the early stages of sleep while potentially reducing the amount of time spent in deeper sleep phases, such as REM sleep.


Q: What does the research say about Neurozepam's use in children or adolescents?

Regulatory documents state that the safety and efficacy of Neurozepam in pediatric patients (under 18 years of age) have not been formally established. Regulatory documents state that safety and efficacy in this age group have not been formally established.


Advertisements

How should Neurozepam be stored and disposed of?

Neurozepam (Bromazepam) tablets must be stored and disposed of according to strict official guidelines to maintain product stability and prevent misuse.

Requirement Official Regulatory Detail
Storage Temperature Store at room temperature, typically defined as below 30^circC (86^circF).
Protection & Handling Must be protected from light and moisture and kept in the original container, which should be tightly closed. The medicine must be stored in a secure location and out of the sight and reach of children due to its controlled substance classification.
Disposal Instructions Disposal must prioritize an authorized drug take-back program. If unavailable, the medicine should be mixed with an undesirable substance, sealed in a container, and discarded in the household trash. It must not be flushed down the toilet unless specifically instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neurozepam found in:

A-Z Index: